NNVC

NanoViricides Inc

May 18 • 04:00PM ET

1.51

+0.03 2.03 %

Healthcare • Biotechnology • USA • Nano • AMEX

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	2.78%	Shs Outstand	21.65M	Perf Week	1.34%
Market Cap	32.69M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	20.99M	Perf Month	10.22%
Enterprise Value	29.48M	PEG	-	EPS next Q	-	Inst Own	8.80%	Short Float	3.40%	Perf Quarter	46.60%
Income	-8.09M	P/S	-	EPS this Y	-	Inst Trans	1.42%	Short Ratio	2.47	Perf Half Y	11.85%
Sales	0.00M	P/B	3.57	EPS next Y	-	ROA	-79.91%	Short Interest	0.71M	Perf YTD	33.63%
Book/sh	0.42	P/C	10.18	EPS next 5Y	-	ROE	-89.97%	52W High	2.23 -32.28%	Perf Year	7.09%
Cash/sh	0.15	P/FCF	-	EPS past 3/5Y	3.77% 23.52%	ROIC	-88.39%	52W Low	0.85 77.65%	Perf 3Y	34.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.03% 10.03%	Perf 5Y	-59.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	37.68%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-95.22%
Dividend Ex-Date	-	Quick Ratio	3.17	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.12	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.17	EPS Q/Q	33.41%	SMA20	7.05%	Beta	1.56	Target Price	6.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	26.20%	Rel Volume	3.86	Prev Close	1.48
Employees	7	LT Debt/Eq	0.00	Earnings	Feb 11	SMA200	17.26%	Avg Volume	289.44K	Price	1.51
IPO	Aug 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.00% -	Trades		Volume	1,138,197	Change	2.03%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-25	Initiated	Alliance Global Partners	Buy
Feb-11-15	Initiated	Midtown Partners	Strong Buy	$5.30

May-18-26 11:55PM	NanoViricides Announces Closing of ~$2 Million Registered Direct Offering (ACCESSWIRE)
08:34AM	NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak (Proactive)
08:30AM	Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides (ACCESSWIRE)
May-15-26 10:02AM	NanoViricides to raise $2M in registered direct offering (Proactive) -14.94%
08:35AM	NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering (ACCESSWIRE)
08:00AM	Loading…
08:00AM	NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II (ACCESSWIRE)
06:18AM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press)
May-12-26 08:35AM	Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs (Exec Edge)
May-11-26 09:00AM	NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak (Proactive)
08:30AM	Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides (ACCESSWIRE)
May-07-26 08:35AM	NanoViricides to Participate at D. Boral Capital Global Conference in NYC (Exec Edge)
May-06-26 03:37PM	NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference (Newsfile)
08:35AM	NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA (Exec Edge)
May-04-26 09:00AM	NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment (Proactive) +15.38%
08:30AM	NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA (ACCESSWIRE)
09:10AM	Loading…
Apr-21-26 09:10AM	NanoViricides says NV-387 could address measles outbreaks as cases rise globally (Proactive)
08:30AM	Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides (ACCESSWIRE)
Apr-11-26 06:22AM	NanoViricides seeks FDAs rare pediatric disease designation for antiviral candidate NV-387 - ICYMI (Proactive)
Apr-09-26 11:24AM	NanoViricides files for Rare Pediatric Disease Designation for Measles Drug (Proactive)
Apr-07-26 09:05AM	NanoViricides seeks rare pediatric disease status for measles drug NV-387 (Proactive) +6.93%
08:30AM	Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides (ACCESSWIRE)
Apr-01-26 09:15AM	NanoViricides to begin Phase II trial of MPox treatment in Congo (Proactive)
08:30AM	Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides (ACCESSWIRE)
Mar-11-26 03:43PM	Dow down, Nasdaq flat as Oracle lifts tech but Gulf shipping attacks eyed (Proactive) +18.32%
09:20AM	NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial (Proactive)
08:30AM	NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete (ACCESSWIRE)
Feb-21-26 11:00AM	NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI (Proactive)
Feb-19-26 03:30PM	Dow Jones leads Wall Street lower, US-Iran fears drive oil higher (Proactive)
08:27AM	NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study (Proactive)
Feb-18-26 06:01PM	NanoViricides advances toward fully funded Phase II MPox trial in DRC (Proactive)
04:54PM	Loading…
Feb-17-26 04:54PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-12-26 03:50PM	Dow drops below 50,000 as S&P 500 falls back under years opening level (Proactive) -7.92%
09:23AM	NanoViricides seeks FDA orphan status for MPox drug (Proactive)
08:30AM	MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides (ACCESSWIRE)
Feb-10-26 09:13AM	NanoViricides seeks orphan drug status with US FDA for measles treatment (Proactive) +8.02%
08:30AM	Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides (ACCESSWIRE)
Feb-02-26 08:30AM	NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres (ACCESSWIRE)
Jan-13-26 08:30AM	NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 (ACCESSWIRE) +6.19%
Dec-12-25 09:51AM	2 Small-Cap Biotechs That Could Reward Patient Investors (MarketBeat)
Dec-01-25 08:30AM	NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles (ACCESSWIRE) -8.20%
Nov-17-25 08:30AM	NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position (ACCESSWIRE)
Nov-14-25 05:41PM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +5.19%
08:30AM	NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 (ACCESSWIRE)
Nov-12-25 05:01PM	NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (ACCESSWIRE) -5.66% -10.00%
Nov-11-25 08:30AM	NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close (ACCESSWIRE) -5.36%
Nov-10-25 08:30AM	NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (ACCESSWIRE) -8.70%
Nov-05-25 08:30AM	NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT (ACCESSWIRE)
Nov-03-25 08:30AM	NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd (ACCESSWIRE) +22.29%
Oct-29-25 08:45AM	Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive (ACCESSWIRE) +21.57%
Oct-27-25 08:45AM	NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 (ACCESSWIRE) +5.23%
Oct-22-25 08:45AM	In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides (ACCESSWIRE)
Oct-20-25 08:45AM	A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus (ACCESSWIRE)
Oct-15-25 08:45AM	NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses (ACCESSWIRE) +6.67%
Sep-30-25 08:45AM	NanoViricides, Inc. Has Filed its Annual Report (ACCESSWIRE)
Sep-11-25 08:30AM	RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 (ACCESSWIRE)
Sep-09-25 08:30AM	NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 (ACCESSWIRE)
Aug-18-25 08:30AM	A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials (ACCESSWIRE)
Jul-30-25 08:30AM	Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides (ACCESSWIRE)
Jul-23-25 08:30AM	NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value (ACCESSWIRE)
Jul-21-25 06:30AM	Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides (ACCESSWIRE)
Jul-16-25 08:30AM	WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides (ACCESSWIRE) +9.59%
Jul-14-25 06:30AM	Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides (ACCESSWIRE) +14.70%
Jul-01-25 06:30AM	There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate (ACCESSWIRE)
Jun-18-25 06:30AM	With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
Jun-04-25 06:55AM	NanoViricides Measles Drug Development Animal Study is Imminent (ACCESSWIRE) +6.80%
May-28-25 06:30AM	NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 (ACCESSWIRE)
May-22-25 06:30AM	The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan (ACCESSWIRE)
May-16-25 06:30AM	NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu (ACCESSWIRE) +7.63%
May-15-25 05:16PM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
May-14-25 06:30AM	Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution (ACCESSWIRE)
May-08-25 06:30AM	Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo (ACCESSWIRE) +13.71%
May-05-25 06:30AM	NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC (Newsfile)
Apr-29-25 06:30AM	Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It (ACCESSWIRE)
Mar-11-25 06:30AM	NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company (ACCESS Newswire) +11.21%
Mar-04-25 06:30AM	Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan (ACCESS Newswire)
Feb-19-25 06:30AM	NanoViricides, Inc. Has Filed its Quarterly Report (ACCESS Newswire)
Feb-14-25 04:37PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
11:29AM	Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? (Insider Monkey)
Feb-11-25 06:30AM	NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape (ACCESS Newswire)
Jan-29-25 06:30AM	NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025 (ACCESS Newswire)
Jan-27-25 06:30AM	NanoViricides Engages CRO for Phase II Clinical Trial (ACCESS Newswire)
Jan-13-25 06:30AM	NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 (ACCESSWIRE) -10.37%
Jan-08-25 06:30AM	Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals (ACCESSWIRE) -9.15%
Dec-23-24 06:30AM	NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape (ACCESSWIRE)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire)
Nov-15-24 06:30AM	NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID (ACCESSWIRE) -8.21%
Nov-14-24 07:20PM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Nov-04-24 12:00AM	NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am (ACCESSWIRE)
Oct-22-24 06:30AM	NanoViricides President Dr. Diwan to Present at the PODD Conference (ACCESSWIRE)
Oct-15-24 06:30AM	NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology (ACCESSWIRE)
Oct-14-24 01:30PM	NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy (Insider Monkey)
Oct-08-24 06:30AM	NanoViricides to Present at the Global AMR Summit 2024 Tomorrow (ACCESSWIRE)
Sep-30-24 06:30AM	NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID (ACCESSWIRE)
Sep-26-24 06:30AM	NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including Trojan Horse Drugs (ACCESSWIRE) +5.19%
Aug-26-24 07:30AM	MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX (ACCESSWIRE) +5.26%
Aug-19-24 06:30AM	NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -?A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections (ACCESSWIRE) -5.07%
Aug-08-24 06:30AM	NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
Aug-02-24 07:00AM	Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses? (Newsfile)
Aug-01-24 06:30AM	"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides (ACCESSWIRE)

NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. It focuses on anti-viral therapeutics through internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Executive ChairmanDr. Anil R. Diwan Ph.D.

M.B.A.Ms. Meeta R. Vyas B.S.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NNVC

NanoViricides Inc

Upgrade your Finviz experience